Extended Infusion of Beta-Lactams Is Associated With Improved Outcomes in Pediatric Patients

• Published in: The journal of pediatric pharmacology and therapeutics 2021, Vol.26 (2), p.187-193
• Main Authors: Zembles, Tracy N, Schortemeyer, Rachael, Kuhn, Evelyn M, Bushee, Glenn, Thompson, Nathan E, Mitchell, Michelle L
• Format: Article
• Language: English
• Subjects: Clinical Investigations
• ISSN: 1551-6776; 2331-348X
• DOI: 10.5863/1551-6776-26.2.187

The pharmacokinetics of beta-lactam antibiotics favor administration via an extended infusion. Although literature supporting extended infusion beta-lactams exists in adults, few data are available to guide the practice in pediatrics. The purpose of this study was to compare clinical outcomes between extended and standard infusions in children. This retrospective chart analysis included hospitalized patients 0 to 18 years old who received at least 72 hours of cefepime, piperacillin-tazobactam, or meropenem between October 1, 2017, and March 31, 2019. Clinical outcomes of care included hospital length of stay, readmission within 30 days, and all-cause mortality. A total of 551 patients (258 extended infusion, 293 standard infusion) met criteria for evaluation. Clinical outcomes among the entire population were similar. A subanalysis of select populations demonstrated decreased mortality in critical care patients (2.1% vs 19.6%, p = 0.006) and decreased 30-day readmission rates in bone marrow transplant patients (0% vs 50%, p = 0.012) who received the extended infusion compared with a standard infusion. Outcomes were similar between extended and standard infusions in children. Subgroup analyses suggest a possible mortality benefit in the critically ill and decreased readmission rate in bone marrow transplant patients.